N-{7-[1-(4'-chlorobiphenyl-2-ylmethyl)azepane-4-yl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazin-3-yl}-4-((R)-3-morpholino-4-yl-1-phenylsulfanylmethylpropylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide | 1274804-19-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{7-[1-(4'-chlorobiphenyl-2-ylmethyl)azepane-4-yl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazin-3-yl}-4-((R)-3-morpholino-4-yl-1-phenylsulfanylmethylpropylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide
• 英文别名: N-{7-[1-(4'-Chloro-biphenyl-2-ylmethyl)-azepan-4-yl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl}-4-((R)-3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-3-trifluoromethanesulfonyl-benzenesulfonamide；N-[7-[1-[[2-(4-chlorophenyl)phenyl]methyl]azepan-4-yl]-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide
• CAS: 1274804-19-1
• 化学式: C₄₅H₅₂ClF₃N₈O₅S₃
• 分子量: 973.605
• InChiKey: SXPGTYZKMYKKJU-RKROREJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  65
• 可旋转键数：
  16
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  184
• 氢给体数：
  2
• 氢受体数：
  16

反应信息

• 作为产物：
  描述：

  7-Boc-3-溴-5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪 在 copper(l) iodide 、 (1S,2S)-(+)-N,N'-二甲基环己烷-1,2-二胺 、 caesium carbonate 、 溶剂黄146 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 163.75h， 生成 N-{7-[1-(4'-chlorobiphenyl-2-ylmethyl)azepane-4-yl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazin-3-yl}-4-((R)-3-morpholino-4-yl-1-phenylsulfanylmethylpropylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide
  参考文献：
  名称：

  [EN] SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER
  [FR] SULFAMIDES UTILISÉS COMME INHIBITEURS DES PROTÉINES DE LA FAMILLE DE BCL-2 DANS LE TRAITEMENT DU CANCER

  摘要：

  本发明涉及一种新型化合物和通过拮抗Bcl-2家族蛋白治疗疾病或紊乱的方法，特别是公式(I)的化合物或其药用盐，以及治疗与Bcl-2抑制相关的疾病、紊乱或综合征的方法，特别是高增殖性疾病。本发明还包括包括公式(I)的化合物和其药用盐的药物组合物。

  公开号：

  WO2011029842A1

文献信息

• SULFONAMIDE COMPOUNDS
  申请人：Miller-Moslin Karen

  公开号：US20120165298A1

  公开（公告）日：2012-06-28

  The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of formula (I): or pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Bcl-2 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.

  本发明涉及一种新型化合物和通过拮抗Bcl-2家族蛋白治疗疾病或障碍的方法，特别是公式(I)的化合物或其药学上可接受的盐，以及治疗与Bcl-2抑制相关的疾病、障碍或综合症的方法，特别是过度增殖性疾病。本发明还包括包含公式I的化合物和其药学上可接受的盐的制药组合物。
• Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer
  申请人：Miller-Moslin Karen

  公开号：US08809352B2

  公开（公告）日：2014-08-19

  The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of formula (I): or pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Bcl-2 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.

  本发明涉及新型化合物及其通过拮抗Bcl-2家族蛋白治疗疾病或疾病的方法，特别是公式(I)的化合物或其药学上可接受的盐，以及治疗与Bcl-2抑制相关的疾病、疾病或综合征的方法，特别是增殖过度性疾病。本发明还包括包括公式I的化合物及其药学上可接受的盐的制药组合物。
• Chemical entities that kill senescent cells for use in treating age-related disease
  申请人：Unity Biotechnology, Inc.

  公开号：US10195213B2

  公开（公告）日：2019-02-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

  本文公开的化合物可有效治疗与衰老有关的各种疾病状态。所公开的化合物可用于消除衰老细胞以治疗疾病。化合物的给药方式包括单次给药和循环给药。
• SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER
  申请人：Novartis AG

  公开号：EP2475661B1

  公开（公告）日：2013-10-23
• COMPOUNDS AND THERAPEUTIC USES
  申请人：Unity Biotechnology, Inc.

  公开号：US20170281649A1

  公开（公告）日：2017-10-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.